42). Aside from size, it is unknown if ARMMs are distinct from canonical microvesicles, possibly being a variant induced by uncharacterized mechanisms or produced by certain cell types. In clinical applications, because of the known reliance on ARRDC1 for ARMM's budding as well as the elevated release of ARMMs in proportion to ARRDC1 overexpression, ARMMs have been used as a vehicle to deliver exogenous, tumour suppressing P53 mRNAs to recipient cells in a in vivo experiment (Ref. 43). The gene discussed is ARRDC1; the disease is neoplasm.